Warren Buffett’s Berkshire Hathaway Inc. has filed a form 4 with the SEC, which shows that the firm has purchased more shares of DaVita. Berkshire Hathaway Inc. is the largest shareholder of the Denver, Colorado based healthcare firm. Warren Buffett has continuously increased his stake in the company over the past several weeks.
Warren Buffett’s Annual Letter: Mistakes, Buybacks and Apple
Warren Buffett published his annual letter to shareholders over the weekend. The annual update, which has become one of the largest events in the calendar for value investors, provided Buffett's views on one of the most turbulent and extraordinary years for the financial markets in recent memory. Q4 2020 hedge fund letters, conferences and more Read More
As of November 4th, Berkshire Hathaway Inc. (NYSE:BRK.A) (NYSE:BRK.B) owned 11.1 million shares of DaVita HealthCare Partners Inc (NYSE:DVA), or 12% of the company. Since November 4th, Berkshire Hathaway Inc. (NYSE:BRK.A) (NYSE:BRK.B) has upped its stake to 11,748,045 shares or 12.4% of outstanding shares. The latest purchase, took place on November 12th, when Berkshire Hathaway Inc. (NYSE:BRK.A) (NYSE:BRK.B) purchased over 48,000 shares of DaVita HealthCare Partners Inc (NYSE:DVA). We will find out more about Berkshire’s purchases when they file their 13F for the third quarter shortly.
Many investors see a strategic benefit from the DaVita HealthCare Partners Inc (NYSE:DVA)/ HCP, Inc. (NYSE:HCP) merger as integrated care networks will likely become increasingly important as we move towards the implementation of health care reform. DaVita’s acquisition of HCP, Inc. (NYSE:HCP) is expected to close by the fourth-quarter of this year. Through the transaction, DaVita HealthCare Partners Inc (NYSE:DVA) is diversifying into a new growth vertical: physician networks. HealthCare Partners is the leading physician network operator with operations in California, Florida, Nevada and New Mexico.
For the nine months ended 30 September 2012, DaVita HealthCare Partners Inc revenues increased 16% to $5.76B. Net income applicable to common stockholders excluding extraordinary items increased 14% to $380.2M. Revenues reflect Dialysis & Related Lab Services segment increase of 15% to $7.03B, Other Ancillary Services & Strategic Initiatives segment increase of 42% to $671.3M.
Disclosure: Long Berkshire, no postion in any other securities mentioned.